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ABSTRACT
The Role of ERp57 in Hras Intracellular Trafficking and Function
by
Jaime Parman
Ras is a central player in signal transduction that mediates cellular proliferation and
differentiation. Recent evidence has shown that lipid and non-lipid modified domains
participate in Ras traffic and that plasma membrane association is mediated by vectorial
vesicular transport from the endomembrane system. ERp57, an ER chaperone, has been
shown to specifically bind farnesylated Hras but not non-farnesylated Hras. The objective of
this study was to determine if ERp57 participates in Ras trafficking and function. First, the
effect of ERp57 knock down by siRNA technology on Hras function was studied; there was a
reduction in ERp57 cellular levels that led to a decrease of active ras. Second, specific antiERp57 antibodies were delivered into 3T3 cells expressing GFP-ras chimeras to observe the
effect on intracellular trafficking. Anti-ERp57 antibodies blocked Hras plasma membrane
localization but not Kras suggesting that ERp57 may be involved in Hras intracellular
trafficking and function.
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CHAPTER 1
INTRODUCTION

Ras is a monomeric GTP-binding protein that is a member of the G-protein
superfamily. Ras serves as a molecular switch that alternates between the active form bound
with GTP and the inactive form bound with GDP. Mutations that constitutively activate ras
proteins have been detected in 30% of all human cancers (Sinensky 2000a). The ras family of
proteins is a central player in the transduction of signals that mediate cellular proliferation and
differentiation. Ras mitogenic signal transduction has been implicated in many cancers, due to
either a direct mutation of the ras protein, or the loss of functioning GTPase activating proteins
(GAP), which terminate the signaling of active ras.
There are 3 major isoforms of ras, Hras, Nras, and Kras4B. All 3 isoforms have a 90%
sequence homology. Hras, Nras, and Kras contain highly conserved domains that interact with
effectors, exchange factors, and guanine-nucleotides. The area in which the isoforms differ
greatly is the hypervariable region, which includes the last 23-25 carboxy-terminal amino acid
residues of the protein. The hypervariable region contains the signal sequences that are required
for ras plasma membrane localization. There are 2 domains of the hypervariable region, the
linker domain and the membrane-targeting domain. The membrane-targeting domain contains
the two signal sequences that cooperate in targeting ras to the plasma membrane (Prior and
Hancock 2001). The first signal sequence is the same for all 3 isoforms of ras, which is
prenylation, the sequential post-translational modification of the CAAX box. The second signal
sequence in Hras and Nras is the palmitoylation of cysteines and a polybasic domain in Kras
(Figure 1). There is evidence that the linker domain contains plasma membrane targeting
information (Prior et al. 2001). The linker domain also regulates the interaction of Hras with
lipid rafts in the plasma membrane and plays a role in regulating the interactions with effector
proteins (Jaumot et al. 2002).
6

Figure 1: Ras Hypervariable Regions. Reprinted from Prior IA, Hancock JF.
Compartmentalization of Ras proteins. J Cell Sci. 2001 May; 114(Pt 9): 1603-8.
Plasma membrane localization is essential for the biological activity of ras (Willumsen et al.
1984). Therefore, the mechanism of ras plasma membrane localization has attracted
considerable attention. The details of ras intracellular trafficking to the plasma membrane are
not entirely understood. However, a model for ras trafficking has been proposed and is
supported by compelling data (Figure 2)(Apolloni et al. 2000).
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Figure 2: Model of Ras Trafficking. Adapted from Apolloni A, Prior IA, Lindsay M, Parton
RG, Hancock JF. H-ras but not K-ras traffics to the plasma membrane through the exocytic
pathway. Mol Cell Biol. 2000 Apr; 20(7): 2475-87.

As mentioned previously, there are 2 signal sequences that are required and must cooperate for
plasma membrane localization of ras. The first signal, the CAAX box (C=cysteine, A=aliphatic
amino acid, X=serine or methionine) is common to all 3 forms of ras and is located at the Cterminus. The CAAX box is sequentially modified, as the cysteine is farnesylated by an enzyme
known as farnesyltransferase (Reiss et al. 1990). Ras then travels to the cytosolic side of the
endoplasmic reticulum (ER) where an endoprotease, RCE1, cleaves AAX, the last 3 residues
from the ras protein, leaving the farnesylated cysteine at the C-terminus (Boyartchuk et al. 1997).
The C-terminal cysteine is then carboxymethylated by a prenylcysteine
carboxymethyltransferase (pcCMT) (Dai et al. 1998). The processed CAAX box must now act
8

in conjunction with a second signal to target ras to the plasma membrane (Choy et al. 1999;
Apolloni et al. 2000; Hancock 1990). Kras is thought to leave this trafficking pathway at this
point because it contains a polybasic domain, a stretch of 6 lysines (175-180), in the
hypervariable region, as its second signal (Hancock 1990). Hras and Nras are further modified
to produce the second signal, the palmitoylation of cysteine 181 in Nras or cysteines 181 and 184
in Hras, which are found in the hypervariable region of the protein (Hancock 1990). Hras and
Nras then enter the secretory pathway by trafficking through the Golgi to the plasma membrane
(Choy et al. 1999; Apolloni et al. 2000), whereas, Kras bypasses the Golgi and traffics to the
plasma membrane through an unidentified pathway (Apolloni et al. 2000). Since the CAAXprocessing enzymes are all ER residents (Dai et al. 1998) and recent data suggest that
palmitoylation occurs at the ER (Choy et al. 1999), the final processing of the CAAX box must
occur on the cytosolic face of the ER membranes. However, this raises the question of how
trafficking of ras proteins from the ER to the plasma membrane occurs after the posttranslational modifications. Recent studies, using green fluorescent protein (GFP) fused to ras
protein creating Ras-GFP chimeras have shown that Nras and Hras are found throughout the
secretory pathway (Choy et al. 1999; Apolloni et al. 2000). To test whether GFP-Nras and GFPHras use vesicular transport to access the plasma membrane experiments were conducted using
Brefeldin A, a drug that disassembles the Golgi apparatus. The results of these experiments
revealed a pronounced accumulation of these proteins in the ER (Choy et al. 1999; Apolloni et
al. 2000), indicating that vesicular transport is required for plasma membrane localization of
Hras and Nras. A 15°C temperature block, which impairs transport from the ER to the Golgi,
was also used to compare the trafficking of Hras and Kras (Choy et al. 1999). These results
demonstrated an accumulation of Hras in the intermediate compartment between the ER and the
9

Golgi. In contrast, however, there was no accumulation of Kras, presumably due to the
polybasic domain excluding Kras from the Golgi (Apolloni et al. 2000). Because the
temperature block or treatment with Brefeldin A did not affect the trafficking of Kras to the
plasma membrane, it can be concluded that palmitoylated Hras and Nras proteins use vesicular
trafficking through the secretory pathway to access the plasma membrane, whereas Kras does not
(Choy et al. 1999; Apolloni et al. 2000). Although Hras and Nras use vesicular transport to
access the plasma membrane, they are not traditionally packaged on the inside of the vesicles;
instead, Hras and Nras must be transported on the cytoplasmic face of the transport vesicles
(Choy et al. 1999). This is where the differential role of the second signal (palmitoylation or a
polybasic domain) may become critical in signaling release from the ER compartment (Apolloni
et al. 2000).
Recent evidence of the role of the carboxy-terminal amino acids of Hras in plasma
membrane localization shows that both lipid-modified and non-lipid-modified domains play a
role in Hras movement throughout the cell and plasma membrane association (Sinensky 2000a).
In addition, Choy et al. discovered that the C-terminus CAAX box is sufficient to target proteins
to the endomembrane system and that localization to the plasma membrane requires a second
signal (Choy et al. 1999). Given that plasma membrane localization of Hras is mediated by
vesicular transport suggests that prenylated cytosolic Hras interacts with specific proteins in the
endomembrane system, which makes Hras accessible for further processing. Because the plasma
membrane is the ultimate destination of Hras, it has been hypothesized that there is a protein that
recognizes both the plasma membrane and the farnesylation of Hras (Rusinol et al. manuscript
under revision). Evidence to support this hypothesis for the existence of such a protein has been
presented by Siddiqui et al. (1998). Siddiqui et al. proposed the “two-site” hypothesis where
10

partner proteins specifically bind to prenylated proteins through the recognition of both the lipid
substituents and the primary sequence of the prenylated protein partner. Previous work by
Rusinol et al. (manuscript under revision) used a combination of ion exchange and affinity
chromatography to identify a prenylation-dependent Hras binding protein, which was confirmed
by ligand blotting (Rusinol et al. manuscript under revision). A 58kDa band was observed as
having the highest binding activity to farnesylated Hras. This 58kDA band showed nearly a
100% sequence homology with a previously cloned protein, which has been identified by
multiple laboratories (Mazzarella et al. 1994; Bourdi et al. 1995,). This protein has been given
multiple names, P58, ER60, Grp58, and ERp57, Rusinol et al. refers to this protein as ERp57 as
will I (Rusinol et al. manuscript under revision). Bourdi et al. isolated the human clone of
ERp57 (1995). ERp57 is a member of the protein disulfide isomerase (PDI) family of enzymes.
ERp57 is found mostly in the ER, but recent evidence has indicated that it is also present in the
cytosol, plasma membrane and nucleus (Johnson et al. 1992; Guo et al. 2002; Coppari et al.
2002). PDI, the best-known member of the family, and ERp57 have been shown to be involved
in the proper folding and formation of disulfide bonds of proteins that are synthesized in the
rough ER. They also function as chaperones and redox-catalysts, which are essential for cell
viability (Turano et al. 2002, Coppari et al. 2002). Rusinol et al. (2003) has shown that ERp57
specifically binds to farnesylated Hras but not non-farnesylated Hras. In this study ERp57 has
been described as a functional partner for Hras, which is consistent with the “two-site”
hypothesis. The objective of the present investigation was to test the hypothesis that ERp57
participates in Hras trafficking to the plasma membrane and therefore is necessary for Hras
function. Primarily two approaches were used to test this hypothesis. The first approach was to
study the effect of an ERp57 knock down by siRNA technology on Hras function. In this
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system, the reduction of ERp57 cellular levels led to a decrease of GTP-bound ras as shown by
interaction with raf1. The second approach was to deliver specific anti-ERp57 antibodies into
live 3T3 cells expressing GFP chimeras with ras and control proteins and then observe the effect
on intracellular trafficking. In this system, anti-ERp57 antibodies blocked Hras localization to
the plasma membrane but not Kras, suggesting that ERp57 may be involved in Hras intracellular
trafficking and function.
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CHAPTER 2
MATERIALS AND METHODS

Plasmids
pEGFP was from Clontech; Kras-GFP was a gift from Dr. Patrick Casey, Duke
University. Hras-GFP fusion protein was created from Hras in pSP64 (Promega, Madison, WI)
by cutting with HindIII, which gives 2 fragments. The larger of the 2 fragments (3.6Kb) was gel
purified using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA). Digestion of the 3.6Kb
fragment with restriction enzyme BamHI gave 2 fragments in agarose gel electrophoresis, a
686bp and a 2.3Kb fragment. The 686bp fragment (ras) was gel purified and directionally
ligated into the vector pEGFP-C3 (Clontech, Palo Alto, CA) to yield the finished construct,
which was confirmed by restriction enzyme analysis.
DNA and Protein Transfections
DNA transfections were done by using GeneJammer from Stratagene (La Jolla, CA).
Protein transfections were done using ProJect from Pierce (Rockford, IL) or Bioproter from
Sigma (St. Louis, MO). All transfections were performed according to manufacturer’s
instructions.
Electrophoresis and Transfer to PVDF Membranes
One-dimensional SDS-PAGE was performed under reducing conditions on a 412%gradient Bis-Tris NuPAGE precast slab gel from Invitrogen (Carlsbad, CA).
Electrophoresis was performed at 200 volts for 45 minutes using the Novex Shurelock System
from Invitrogen. Broad range pre-stained protein markers from Invitrogen were used to estimate
the relative molecular masses of the proteins. Electrophoretic transfer to PVDF membranes
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(Millipore) was performed in 20mM Tris-HCL and 0.15M glycine 10% methanol buffer, pH 8.1,
for 60 minutes at 60 volts.
Western Blot
After transfer to PVDF, membranes were blocked for 1 hour in 5% nonfat milk in trisbuffered saline containing 0.1%Tween 20 (TBS-T). PVDF membranes were then probed with
antibodies. Membranes were incubated with primary antibody; diluted 1:1000 in 5% nonfat milk
in TBS-T solution, either anti-ERp57 (Stressgen, Victoria, BC), anti-Hras (Santa Cruz
Biotechnology, Santa Cruz, CA), anti-Kras (Calbiochem, San Diego, CA) or anti-Pan-ras
(Oncogene, San Diego, CA), for 1 hour and washed 3 times for 5 minutes each. After
washing, membranes were then incubated with secondary antibody; diluted 1:25000 in 5%
nonfat milk in TBS-T solution, either goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology,
Santa Cruz, CA) or goat anti-mouse IgG-HRP (Pierce, Rockford, IL), for 1 hour and washed as
before. Antibody-bound proteins were detected by chemiluminescence from Pierce. The
membranes were then exposed to X-ray film to visualize the proteins.
Immunofluorescence
3T3 cells were grown on glass coverslips overnight. After washing with PBS, cells were
fixed in freshly prepared 4% paraformaldehyde in PBS, pH 7.3. After fixation, cells were
incubated for 1 hour with anti-human ERp57 specific rabbit polyclonal antibodies (Stressgen,
Victoria, BC), diluted 1:100 in 5% BSA in PBS, rinsed 3 times with PBS, and then stained for 1
hour with FITC-conjugated anti-rabbit IgG or Texas Red-conjugated anti-rabbit IgG (Stressgen,
Victoria, BC), diluted 1:500 in 5% BSA in PBS. For co-localization experiments, cells were also
incubated with mouse monoclonal anti-PMCA ATPase antibodies (Affinity BioReagents,
Golden, CO) and Texas Red- conjugated anti-mouse IgG (Stressgen, Victoria, BC). Cells were
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then mounted in a special medium for fluorescence (Prolong Anti-fade, Molecular Probes) and
observed. Confocal images were obtained by digital deconvolution of 10-slice stacks acquired
on a Nikon Diaphot 200 equipped with a Photometrics Sensys cooled CCD digital camera or
Nikon D100, Oncor Z-drive and Oncor image software.
Co-immunoprecipitations
Co-immunoprecipitation assays were performed using Seize Coated Plate
immunoprecipitation Kits from Pierce (Rockford, IL) according to manufacturer’s instructions.
3T3 cells were grown briefly in DMEM 10% FBS medium and then scraped and solubilized in a
buffer containing Triton X-100 to a protein concentration of 1mg/ml. Cell lysates were then
incubated with primary antibodies, either anti-Hras or anti-Kras, immobilized onto 96-well plates
coated with protein A/G. After binding, washing, and elution, the co-presence of ras and ERp57
in the precipitates was examined by immunoblotting.
VSVG Intracellular Trafficking
Dr. Jennifer Lippincott-Schwartz (National Institutes of Health, Bethesda, MD) kindly
provided a vector expressing a temperature sensitive VSVG-GFP chimera (Presley et al. 1997).
3T3 cells were transiently transfected with VSVG-GFP and cultured at 40°C. After 16 hours at
40°C, cells were transfected with anti-ERp57 antiserum and incubated for 6 hours, then switched
to 32°C for 3 hours. VSVG-GFP localization was then determined by fluorescence microscopy
and digital deconvolution as described previously.
siRNA Construction and Transfections
pSilencer from Ambion (Austin, TX) was used in siRNA experiments. Target sites for
siRNA in ERp57 were selected using Ambion’s siRNA target finder and design tool that follows
the current guidelines for siRNA design. Based on the target sequences, 5 complementary
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oligonucleotide pairs (4 with correct sequences plus 1 randomized sequence) were custom
synthesized. The oligos were then allowed to anneal, creating ApaI and EcoRI overhangs.
siRNA generating vectors were constructed by ligating the annealed oligos into linearized
pSilencer vector. The finished siRNA plasmid was transfected into 3T3 cells as described above.
Detection of Ras Activation
Active ras in 3T3 cell lysates was detected using the EZ-Detect Ras Activation Kit
from Pierce (Rockford, IL). Cell lysates were treated according to manufacturer’s instructions.
Then the pulled-down active ras was detected by Western Blot using anti-ras antibody.

16

CHAPTER 3
RESULTS
Previous experiments by Rusinol et al. used HeLa cells in ERp57 localization
experiments. The Ras-GFP chimeras that were used in this study are stably expressed in 3T3
cells, because 3T3 cells are larger and allow for easier observation of intracellular trafficking.
Therefore, it was necessary to determine where ERp57 localizes in 3T3 cells. This was
determined by standard immunofluorescence, which is explained in materials and methods. The
results show that ERp57 is localized mostly in the ER but is also present in the plasma
membrane of 3T3 cells as indicated by the arrows in figure 3.
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Figure 3: Detection of ERp57 in 3T3 Cells. A representative cell of several experiments is
shown. Localization of ERp57 was observed mostly in the ER but is also seen in the plasma
membrane of 3T3 cells as indicated by the arrows.

To confirm that ERp57 was in fact localized in the plasma membrane, a co-localization
experiment was performed as a control, using an anti-PMCA ATPase antibody as a plasma
membrane marker. Figure 4 shows the results of the co-localization between ERp57 and the
calcium pump of the plasma membrane (PMCA ATPase) in 3T3 cells. PMCA-ATPase showed
a typical plasma membrane staining whereas ERp57 showed a cytoplasmic distribution (mostly
ER) but also showed plasma membrane staining which is seen with the co-localization of
PMCA-ATPase in many areas. These results are consistent with partial ERp57 localization to
the plasma membrane as previously reported in other cell types (Wyse et al. 2001; Guo et al.
2002) as well as the isolation of ERp57 from our purified plasma membrane preparations
18

(Rusinol et al. manuscript under revision). Since trafficking of Hras begins in the ER and
terminates in the plasma membrane, the co-localization of ERp57 at the plasma membrane is
consistent with the hypothesis that ERp57 plays a role in Hras trafficking.

ERp57

10µm

PMCA-ATPase

10µm

Merge

10µm

Figure 4: Subcellular Localization of ERp57 in 3T3 Cells. The subcellular distributions of
ERp57 and plasma membrane calcium ATPase (PMCA-ATPase) were determined in 3T3 cells
by indirect immunofluorescence as described in Materials and Methods. Cells were visualized by
fluorescence microscopy and digital deconvolution. Images represent single digitally
deconvolved sections. Shown is a representative cell of several experiments. The panel on the
right is an overlay of the ERp57 and PMCA ATPase images and shows numerous areas of colocalization in the plasma membrane (yellow).
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Data from Rusinol et al. have shown that ERp57 and Hras interact in vitro, but not in
vivo (Rusinol et al. manuscript under revision). To determine if ERp57 is able to associate with
Hras in vivo, co-immunoprecipitation experiments were performed. As described in materials
and methods, 3T3 cells were solubilized in Triton-X100 buffer and centrifuged to remove the
insoluble fraction. The cell lysate (soluble fraction) was immunoprecipitated with monoclonal
anti-Hras and anti-Kras antibodies. The immunoprecipitates were then analyzed by
immunoblotting for the presence of Hras, Kras and ERp57. Figure 5 shows that the anti-Hras
antibodies immunoprecipitated Hras and ERp57 (Figure 5A) and that the anti-Kras antibodies
immunoprecipitated Kras but not ERp57 (Figure 5B). The specificity of this reaction was
confirmed by showing that the anti-ras antibodies did not precipitate other molecular chaperones,
such as GRP94 and PDI (Figure 5C).
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Figure 5: Co-immunoprecipitation of ERp57 and Ras. 3T3 lysates were immunoprecipitated
with rabbit polyclonal anti-Hras (A) rabbit polyclonal anti-Kras (B) or mouse monoclonal antipan-ras antibodies (C). A) The immunoprecipitates from anti-Hras antibodies were separated by
SDS-PAGE, blotted, and probed with rabbit anti-Hras and rabbit anti-ERp57 antibodies. B) The
immunoprecipitates from anti-Kras antibodies were probed with rabbit anti-Kras and rabbit antiERp57 antibodies. A control lane in which anti-ras antibodies were omitted showed no
detectable ERp57. TCL: positive control with equivalent amount of total cell lysate loaded on
the gel. NR: TCL after immunoprecipitation with a pre-immune antibody. Anti-H: TCL after
immunoprecipitation with anti-Hras antibodies. Anti-K: TCL after immunoprecipitation with
anti-Kras antibodies. IP (A): ERp57 and Hras were immunoprecipitated with anti-Hras
antibodies. IP (B): Kras was immunoprecipitated with anti-Kras antibodies, but no ERp57 was
present. C) The immunoprecipitates formed by treatment with anti-pan-ras antibodies were
tested for the presence of other chaperones. IP: immunoprecipitates were blotted and probed for
GRp94 and protein disulfide isomerase. TCL: equivalent amount of total cell lysate.
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Role of ERp57 in Hras Trafficking
In order to test the hypothesis of the involvement of ERp57 in Hras intracellular
trafficking and function, we reduced the cellular levels of ERp57 using 2 methods, siRNA
technology and peptide mediated protein delivery. siRNA is a technique that is used to reduce
the expression of a specific gene in living cells by introducing a homologous dsRNA. Once
inside the cell, the dsRNAs are cleaved into short 21-25 nucleotide siRNAs. The siRNAs
assemble into an RNA-induced silencing complex (RISC) where it is unwound and activated.
This allows the siRNA antisense strand and mRNA to bind to their complementary transcript by
base pairing interactions. Gene silencing is the result of sequence specific cleavage of the
mRNA-siRNA-RISC complex. This technology was used to study the functional consequences
of reducing ERp57 expression. There are 5 ways to produce siRNAs; we chose to use a siRNA
expression plasmid, the pSilencer vector from Ambion (Austin, TX). Target sequences were
designed to reduce the cellular expression of ERp57. The knockdown experiments were
performed by ligating the target sequences into the pSilencer vector then transfecting 3T3 cells
and 3T3 cells expressing GFP-Hras chimeras with the pSilencer  construct. The total cell
expression of ERp57 in the transfected cells was then analyzed by Western blot (Figure 6).
Figure 6 shows that the cellular levels of ERp57 in 3T3 cells are reduced by siRNA expression
over time. The transfected cells were observed by fluorescence microscopy at the different time
points to observe the effect of reduced ERp57 levels, by siRNA expression, on Hras plasma
membrane localization. Figure 7 indicates that the reduction of ERp57 blocks the intracellular
trafficking of Hras-GFP to the plasma membrane.
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Figure 6: ERp57 Levels in 3T3 Cells Are Reduced by siRNA Expression. Cells were
transfected with empty pSilencer vector as a control and with the pSilencer-ERp57 siRNA
construct then lysed at different time points. Total cells lysates were separated by SDS-PAGE
and then analyzed by Western Blot using anti-ERp57 antibodies. The level of ERp57 in 3T3
cells was drastically reduced, 48 hours after transfection, by siRNA expression, as compared to
the control where the level of ERp57 is constant.

The transfected cells were observed by fluorescence microscopy at the different time points to
observe the effect of reduced ERp57 levels, by siRNA expression, on Hras plasma membrane
localization (Figure 7). Figure 7 indicates that the reduction of ERp57 blocks the intracellular
trafficking of Hras-GFP to the plasma membrane.
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Figure 7: Reduction of ERp57 Expression Blocks Hras-GFP Intracellular Trafficking. 3T3 cells
stably expressing Hras-GFP were transfected with the pSilencer-ERp57 siRNA randomized
sequence (control) and the pSilencer-ERp57 siRNA construct. Cells were observed by
fluorescence microscopy. Shown is a representative cell of several experiments. This figure
shows that 48 hours after transfection, Hras-GFP traffic to the plasma membrane is blocked as
compared to the control where there is clear plasma membrane localization.
Because the reduced levels of ERp57 had such a dramatic effect on Hras-GFP trafficking to the
plasma membrane, we examined whether the reduction ERp57 expression had any effect on the
activation of ras in 3T3 cells. The EZ-Detect Ras Activation Kit from Pierce (Rockford, IL)
was used for this experiment. The kit uses the Ras-binding domain of Raf1, and specifically
“pulls down” active ras (GTP bound) out of cell lysates. The proteins that were “pulled down”
were separated by SDS-PAGE and then analyzed by Western Blot using anti-ras antibodies,
which is shown in figure 8.
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(72h)

24h

48h
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Figure 8: Reduction of ERp57 Expression Hinders Ras Activation. Cells were transfected with
empty pSilencer vector as the control and the pSilencer-ERp57 siRNA construct. Cells were
lysed at different time points then analyzed by Western Blot using anti-ras antibodies. The
amount of active ras in the cell lysate was then determined using the Raf-1 binding domain of
ras. This figure shows that overtime the amount of active ras in 3T3 cells was decreased due to
reduction of ERp57 expression.
In the second approach, the ability of ERp57 antibodies to inhibit the trafficking of Hras
was confirmed in whole cells. This was done by examining the effect of transfection with
ERp57 antibodies on the intracellular localization of Hras-GFP chimeras expressed in 3T3 cells.
ERp57 antibodies were introduced into the cells by a peptide carrier technology (Morris et al.
2001), in which proteins are delivered into the cytosol of transfected cells. Figure 9 shows the
effect of ERp57 antibodies on the intracellular localization of GFP chimeras with full-length
Hras and an Hras 21a.a. C-terminal fragment (HrasCT). Control experiments were done by
transfecting the Hras-GFP or HrasCT-GFP cells with non-immune serum, which shows plasma
membrane localization as well as cytoplasmic staining (Figure 9A, C). Our results were
consistent with previous results reported by Choy et al. for expression of these GFP constructs in
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3T3 cells (Choy et al. 1999). However, transfection with the ERp57 antibody resulted in the
accumulation of Hras-GFP in intracellular vesicles, possibly the ER, in both constructs (Figure
9B, D).

A control

B + Anti-ERp57

C control

D + Anti-ERp57

Figure 9: Anti-ERp57 Antibodies Block the Trafficking of Full-length Hras and HrasCT-GFP to
the Plasma Membrane. 3T3 cells stably expressing full-length Hras-GFP or HrasCT-GFP were
transfected with anti-ERp57 antibodies. The location of the GFP chimeras was then assessed by
fluorescence microscopy followed by digital deconvolution of the acquired images. Shown is a
representative cell of several experiments. When cells expressing full-length Hras-GFP (A) or
HrasCT-GFP (C) were transfected with the protein delivery reagent only, clear plasma
membrane localization was observed. When cells were transfected with 2µg/ml of anti-ERp57
antibodies, traffic of both chimeras to the plasma membrane was completely blocked (B and D).
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To examine the specificity of the inhibition of Hras trafficking by ERp57 antibodies,
relative to another protein that uses the secretory pathway to access the plasma membrane, the
effect of transfection with ERp57 antibodies on the trafficking of VSVG protein was examined.
For the studying of this protein, we used a previously reported system (Presley et al. 1997), in
which a temperature sensitive mutant of VSVG (tsVSVG) was used. At a nonpermissive
temperature of 40°C the tsVSVG-GFP is unable to exit the ER (Figure 10A). However, at the
permissive temperature of 32°C the tsVSVG-GFP is allowed to traffic using the secretory
pathway to show clear plasma membrane and Golgi localization (Presley et al. 1997)(Figure
10C). The tsVSVG-GFP was transiently expressed in 3T3 cells then transfected with antiERp57 antibody (Figure 10B, D). Co-transfection with Texas-Red conjugated anti-rabbit IgG
was used to monitor transfection of the antibody into individual cells. Texas-Red positive cells
were then examined for the localization of the green tsVSVG. The results observed in Figure 10
show that the cells transfected with anti-ERp57 antibodies and switched to 32 °C had no effect
on the transport of VSVG-GFP to the plasma membrane (Figure 10D).
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A
A

B
B

+ Anti-ERp57 @ 40oC

C

D

+ Anti-ERp57 @ 32oC

Figure 10: Anti-ERp57 Antibodies Do Not Affect tsVSVG Traffic to the Plasma Membrane. 3T3
cells transiently expressing tsVSVG and cultured at 40 °C were transfected with pre-immune
antiserum (not shown) or antiERp57 antibodies. Texas Red-mouse IgG was also included as a
marker for transfection (A, C). Cells were incubated for 6h at 40 °C in regular growth medium.
Cells were then maintained at 40 °C (B), or switched to 32 °C (D). VSVG-GFP traffic to plasma
membrane was determined in Texas-red positive cells after 3h by fluorescence microscopy.
Images represent single digitally deconvolved sections. Shown is a representative cell of several
experiments. This experiment indicates that ERp57 antibodies did not block plasma membrane
localization of tsVSVG at the permissive temperature (D).
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As previously mentioned, Kras is farnesylated but contains a different second signal
sequence from Hras for targeting the protein to the plasma membrane and does not traffic to the
plasma membrane through the secretory pathway. Because ERp57 specifically recognizes
farnesylated Hras, it was of interest to determine whether ERp57 played a role in Kras traffic as
well. This would be allowed to happen if, for example, ERp57 had a role in transporting ras
proteins between various ER enzymes that were involved in their post-translational modification.
This idea was tested using the same peptide carrier technology as described above. ERp57
antibodies were transfected into 3T3 cells stably expressing Kras-GFP. Co-transfection with
Texas-Red conjugated anti-mouse IgG was used to monitor transfection of the antibody into
individual cells. Texas-Red positive cells were then examined by fluorescent microscopy to
determine the effect on the localization of the Kras-GFP. The results shown in Figure 11
indicate that the transfection of Kras-GFP cells with ERp57 antibodies had no affect on the
plasma membrane localization of Kras.
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A

Control

B

C

+ Anti-ERp57

Figure 11: Anti-ERp57 Antibodies Do Not Affect Kras Traffic to the Plasma Membrane. 3T3
cells stably expressing Kras-GFP (A) were transfected with Texas-Red mouse IgG as a marker
for transfection (B) and with anti-ERp57 antibodies (C). The red cells were then examined for
the localization of the green Kras-GFP by fluorescence microscopy followed by digital
deconvolution of the acquired images. Shown is a representative cell of several experiments.
This experiment shows that blocking ERp57 function has no impact in Kras plasma membrane
localization.

This is consistent also with the hypothesis that Hras and Kras traffic to the plasma membrane via
different routes. Together with the results shown in Figure 9, these data strongly suggest a role
for ERp57 in the specific targeting of Hras to the plasma membrane. This also suggests that
although ERp57 recognizes the farnesylated Hras, ERp57 must interact with Hras somewhere
within the secretory pathway because Kras is farnesylated as well, but ERp57 antibodies do not
affect its trafficking. This result is consistent with our previous result shown in figure 5B, that
Kras and ERp57 do not interact as shown by co-immunoprecipitation and ligand blot.
30

CHAPTER 4
DISCUSSSION
Previous studies reported from Siddiqui et al. suggested the “two site” hypothesis, where
partner proteins specifically bind to prenylated proteins through the recognition of both the lipid
substituents and the primary sequence of the prenylated protein partner (Siddiqui et al. 1998;
Sinensky 2000b). The present study was motivated by this hypothesis, and supported by
previous data, that post-translational lipidation of proteins serves to mediate heterodimeric
protein-protein interactions (Rusinol et al. manuscript under revision).
Consistent with the “two-site” hypothesis, the current study describes a functional partner
for Hras. ERp57 has been identified as the heterodimer for Hras because of its ability to bind
farnesylated Hras relative to non-farnesylated Hras by ligand blotting. Data from previous work
have shown that Hras and ERp57 interact in vitro, but do not prove that the 2 proteins associate
in vivo in 3T3 cells or HeLa cells (Rusinol et al manuscript under revision). The results of the
co-immunoprecipitation experiments in this study (Figure 5), where the anti-Hras antibody
precipitated ERp57, indicate that ERp57 and ras do interact in vivo in 3T3 cells. The siRNA
experiments also indicate that there is a connection between ERp57 and ras localization because
the reduction of cellular levels of ERp57 hindered the localization of Hras at the plasma
membrane in Hras-GFP cells. This suggests that ERp57 may also be required for the correct
folding of another protein that targets Hras.
Hras has been proven to traffic from the ER to the plasma membrane using the secretory
pathway (Choy et al. 1999; Apolloni et al. 2000). The blockage of Hras trafficking by antiERp57 antibodies can be observed in vitro and in vivo. The specificity of this interaction was
confirmed in respect to VSVG protein. The results of this experiment argue against the blockage
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of Hras trafficking being a consequence of a global inhibition of the secretory pathway. Many
laboratories have demonstrated that Hras plasma membrane localization is dependent on
farnesylation (Willumsen et al. 1984; Cox et al. 1995). Other studies have also shown that
mutations present in the hypervariable region of Hras do not affect its lipidation but do prevent
correct targeting to the plasma membrane (Willumsen et al. 1996; Jaumot et al. 2002). However,
based on our current study we cannot eliminate the possibility that the acyl group of Hras is the
second recognition site for ERp57.
Our observations suggest a binding protein that mediates Hras trafficking, ERp57, that
recognizes both the lipid moiety and possibly another structural element of Hras. The specificity
for inhibition of Hras trafficking relative to Kras trafficking by ERp57 antibodies supports these
observations. The CAAX box of Hras and Kras are both sequentially modified in the same
manner; however, farnesylation alone is not sufficient enough to target the proteins to the plasma
membrane. Hras and Kras both must ultimately arrive at the plasma membrane for function, but
how they reach this final destination is very different from each other. It is believed that the
second signal sequence in the hypervariable region, palmitoylation for Hras and Nras or the
polybasic domain for Kras, serves as a sorting signal that specifies which pathway for the protein
to take (Hancock et al. 1990; Apolloni et al. 2000). Although Hras and Kras have many
similarities, Kras is known to traffic by a different mechanism from Hras (Thissen et al. 1997;
Apolloni et al. 2000; Chen et al. 2000). Thus, we have demonstrated that the specificity for Hras
trafficking on ERp57 compared to VSVG and Kras are consistent with the functional role of
ERp57 as a chaperone molecule for Hras trafficking operating through the “two-site” recognition
mechanism (Rusinol et al. manuscript under revision).
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ERp57 has been shown to associate with other molecular chaperones such as, calnexin
and calreticulin, this occurs in the lumen of the ER (Zapun et al. 1998). It has also been reported
that ERp57 is associated with the plasma membrane lipid rafts (Guo et al. 2002). The lipid rafts
present in the plasma membrane of cells have also been shown as an anchoring point for Hras in
the plasma membrane (Prior et al. 2001). The interaction of ERp57 and Hras would not be
expected to occur in the lumen of the ER because the CAAX processing and plasma membrane
targeting of Hras takes place on the cytoplasmic side of the ER. This was demonstrated in the
present study by the trafficking of full-length Hras and the C-terminal 21 a.a. of Hras was
blocked by the delivery of anti-ERp57 antibodies into the cytosol of 3T3 cells. This suggests
that the site of Hras-ERp57 interaction is located on the cytoplasmic side of the ER/Golgi or the
cytosol (Rusinol et al. manuscript under revision).
The mechanism by which ERp57 participates in Hras traffic is not obvious from the
present study. However, because the ERp57 antibodies do not interfere with the trafficking of
Kras, it is unlikely that ERp57 has a role in CAAX processing. Therefore, it would be expected
that ERp57 plays a role in the vesicular trafficking in the secretory pathway, but this also is
unlikely because of the lack of effect of ERp57 antibodies on the trafficking of VSVG protein.
Instead, the specificity of inhibition of Hras trafficking compared to that of Kras and VSVG by
ERp57 antibodies indicates that ERp57 acts at one or more biochemically distinct steps in the
Hras trafficking pathway (Rusinol et al. manuscript under revision). Given the steps that Kras
and VSVG have in common with Hras trafficking, the possible site of action for ERp57 should
occur after CAAX box processing and before entry into the secretory pathway at the Golgi. Hras
trafficking through the secretory pathway requires CAAX processing and palmitoylation, to
allow for the specific targeting of Hras to the caveolin-enriched plasma membrane microdomains
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(Li et al. 1996). In contrast, Kras traffics to the plasma membrane using a different route, which
as we show does not require ERp57 function, and associates with the non-caveolin regions of the
plasma membrane (Choy et al. 1999; Roy et al. 1999; Apolloni et al. 2000). However, because
ERp57 has been proven to interact with lipid rafts in the plasma membrane (Guo et al. 2002) we
are able to speculate the possibility that ERp57 could mediate the final destination of Hras to the
caveolin-enriched plasma membrane microdomains (Rusinol et al. manuscript under revision).
The mechanism by which ERp57 participates in Hras function can possibly defined by the
isolation and characterization of the large vesicles that contain Hras and are known to
accumulate upon ERp57 inhibition (Rusinol et al. manuscript under revision).
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Figure 12: Model of Ras Trafficking with Potential Erp57 Interaction Sites. Based on our
observations the potential sites for ERp57 to interact with Hras have been added to the ras trafficking
model. Adapted from Apolloni A, Prior IA, Lindsay M, Parton RG, Hancock JF. H-ras but not K-ras
traffics to the plasma membrane through the exocytic pathway. Mol Cell Biol. 2000 Apr; 20(7): 247587.
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APPENDIX
LIST OF ABBREVIATIONS

a.a.

amino acid

BSA

bovine serum albumin

bp

base pair

DNA

deoxyribonucleic acid

DMEM

Dulbecco’s Minimal Essential Medium

dsRNA

double-stranded RNA

ER

endoplasmic reticulum

FBS

fetal bovine serum

FITC

fluorescein isothiocyanate

FTase

farnesyl transferase

GAP

GTPase activating protein

GDP

guanine diphosphate

GTP

guanine triphosphate

HrasCT

Hras 21aa C-terminal fragment

IgG

immunoglobulin G

IP

immunoprecipitate

Kb

kilobase

kDa

kilodaltons

mRNA

messenger RNA

oligo

oligonucleotide

PalmTase

palmitoyl transferase

PBS

phosphate buffered saline

pcCMT

prenylcysteine carboxymethyltransferase
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PDI

protein disulfide isomerase

PMCA ATPase

Calcium pump of the plasma membrane

PVDF

polyvinylidene fluoride

RISC

RNA-induced silencing complex

RNA

ribonucleic acid

SAM

S-adenosyl methionine

SDS-PAGE

sodium dodecyl sulfate polyacrylamide gel electrophoresis

siRNA

small interfering RNA

TCL

total cell lysate

tsVSVG

temperature sensitive vesicular stomatitis virus glycoprotein

VSVG

vesicular stomatitis virus glycoprotein
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